January | February | March | April |
Last updated: April 25, 2024
|
Company | Location | Gross (US$M) | Round | Date |
Accent Therapeutics Inc. | Lexington;Massachusetts;United States | 75 | Series C | 1/23/2024 |
Acousia Therapeutics GmbH | Tübingen;Baden-Württemberg;Germany | 1/9/2024 | ||
Anacardio AB | Stockholm;Stockholm;Sweden | 4.7 | Series A | 1/17/2024 |
Aqemia SAS | Paris;Île-de-France;France | 32.5 | 1/30/2024 | |
Aravax Pty Ltd. | Melbourne;Victoria;Australia | 22 | Series B | 1/29/2024 |
Avistone Biotechnology Co. Ltd. | Beijing;Beijing;China | 140 | Series B | 1/4/2024 |
Beckley Psytech Ltd. | Oxford;England;United Kingdom | 50 | 1/4/2024 | |
Bolden Therapeutics Inc. | Providence;Rhode Island;United States | 1.5 | 1/17/2024 | |
Bolden Therapeutics Inc. | Providence;Rhode Island;United States | 1/10/2024 | ||
Calluna Pharma Inc. | Oslo;Oslo;Norway | 81.3 | Series A | 1/23/2024 |
Casinvent Pharma | Prague;Hlavní m?sto Praha;Czech Republic | 1.7 | 1/30/2024 | |
Clarametyx Biosciences Inc. | Columbus;Ohio;United States | 33 | Series A | 1/8/2024 |
Claris Bio Inc. | Jersey City;New Jersey;United States | 57 | Series A | 1/4/2024 |
Comanche Biopharma Corp. | Concord;Massachusetts;United States | 75 | Series B | 1/17/2024 |
Cour Pharmaceuticals Development Co. Inc. | Chicago;Illinois;United States | 105 | Series A | 1/30/2024 |
Cumulus Oncology Ltd. | Edinburgh;Scotland;United Kingdom | 11.5 | Seed | 1/8/2024 |
Cyrano Therapeutics Inc. | Delray Beach;Florida;United States | 9 | Series B | 1/16/2024 |
Delsitech Ltd. | Turku;Southwest Finland;Finland | 10.8 | 1/16/2024 | |
Disco Pharmaceuticals GmbH | Cologne;North Rhine-Westphalia;Germany | 21.7 | Seed | 1/16/2024 |
Enterprise Therapeutics Ltd. | Brighton;England;United Kingdom | 33.1 | Series B | 1/30/2024 |
Enyo Pharma SA | Lyon;Auvergne-Rhône-Alpes;France | 42.5 | Series C | 1/3/2024 |
Eyconis Inc. | Redwood City;California;United States | 150 | 1/29/2024 | |
Genecraft Inc. | Songpa-gu;Seoul;South Korea | 7.48 | Series A | 1/19/2024 |
Graviton Bioscience Corp. | New York City;New York;United States | Financing agreement | 1/2/2024 | |
Halia Therapeutics Inc. | The Lehi;Utah;United States | 30 | Series C | 1/31/2024 |
Hephaistos-Pharma | Orsay;Île-de-France;France | 2.2 | Seed | 1/23/2024 |
Human Immunology Biosciences Inc. | South San Francisco;California;United States | 95 | Series B | 1/4/2024 |
IMU Biosciences Ltd. | London;England;United Kingdom | 14.7 | Series A | 1/24/2024 |
Ji Xing Pharmaceuticals Ltd. | Shanghai;Shanghai;China | 162 | Equity investment | 1/9/2024 |
Maps Public Benefit Corp. | San Jose;California;United States | 100 | Series A | 1/10/2024 |
Mimivax Inc. | Buffalo;New York;United States | 1/10/2024 | ||
Mitosense Inc. | Plymouth;Massachusetts;United States | 3.5 | Seed | 1/22/2024 |
Moonwalk Biosciences Inc. | South San Francisco;California;United States | 57 | Seed and series A | 1/4/2024 |
Myrobalan Therapeutics Inc. | Medford;Massachusetts;United States | 24 | Series A | 1/10/2024 |
Nodus Oncology Ltd. | Edinburgh;Scotland;United Kingdom | 2.3 | Seed | 1/11/2024 |
Oncusp Therapeutics Inc. | New York City;New York;United States | 100 | Series A | 1/4/2024 |
Prism Biolab Co. Ltd. | Tokyo;Tokyo;Japan | 10.3 | Series C | 1/24/2024 |
Prota Therapeutics Pty Ltd. | Melbourne;Victoria;Australia | 21 | Equity and debt financing | 1/16/2024 |
Radionetics Oncology | San Diego;California;United States | 52.5 | Series A | 1/3/2024 |
Ratio Therapeutics Inc. | Boston;Massachusetts;United States | 50 | Series B | 1/17/2024 |
Remix Therapeutics Inc. | Cambridge;Massachusetts;United States | 60 | 1/3/2024 | |
Resalis Therapeutics srl | Turin;Piedmont;Italy | 10.9 | Series A | 1/4/2024 |
Stalicla SA | Genève;Geneva;Switzerland | 17.4 | Series B | 1/16/2024 |
Synnovation Therapeutics Inc. | Wilmington;Delware;United States | 102 | Series A | 1/24/2024 |
Tr1x Inc. | San Diego;California;United States | 75 | Series A | 1/17/2024 |
Utility Therapeutics Ltd. | London;England;United Kingdom | 1/17/2024 | ||
Vasa Therapeutics Inc. | Encinitas;California;United States | 6 | Seed | 1/3/2024 |
Vico Therapeutics BV | Leiden;South Holland;Netherlands | 60 | Series B | 1/5/2024 |
Zwi Therapeutics Inc. | Watertown;Massachusetts;United States | 10 | Series A | 1/24/2024 |
Alys Pharmaceuticals Inc. | Boston;Massachusetts;United States | 100 | Seed | 2/12/2024 |
Anbogen Therapeutics Inc. | Taipei;Taiwan;Taiwan | 12.5 | Series A | 2/2/2024 |
Areteia Therapeutics Inc. | Chapel Hill;North Carolina;United States | 75 | Series A | 2/13/2024 |
Attralus Inc. | San Francisco;California;United States | 56 | 2/7/2024 | |
Baseimmune Ltd. | London;England;United Kingdom | 11 | Series A | 2/26/2024 |
Basking Biosciences Inc. | Columbus;Ohio;United States | 55 | 2/1/2024 | |
Bioage Labs Inc. | Richmond;California;United States | 170 | Series B | 2/13/2024 |
Blossomhill Therapeutics Inc. | San Diego;California;United States | 100 | Series B | 2/29/2024 |
Curve Therapeutics Ltd. | Southampton;England;United Kingdom | 51.2 | Series A | 2/27/2024 |
Firefly Bio Inc. | South San Francisco;California;United States | 94 | Series A | 2/15/2024 |
Frontier Medicines Corp. | Boston;Massachusetts;United States | 80 | Series C | 2/23/2024 |
Insamo Inc. | Berkeley;California;United States | 12 | Seed | 2/21/2024 |
Isomab Ltd. | Nottingham;England;United Kingdom | 9.4 | Seed | 2/21/2024 |
Kenai Therapeutics Inc. | San Diego;California;United States | 82 | Series A | 2/29/2024 |
Latigo Biotherapeutics Inc. | Thousand Oaks;California;United States | 135 | Series A | 2/14/2024 |
Limmatech Biologics AG | Schlieren;Zurich;Switzerland | 3 | 2/1/2024 | |
Matter Neuroscience | New York City;New York;United States | 26 | Seed | 2/27/2024 |
Metabolica Health Inc. | New York City;New York;United States | 1 | Private placement | 2/27/2024 |
Neophore Ltd. | London;England;United Kingdom | 12.2 | Series B | 2/1/2024 |
Neurenati Therapeutics | Montreal;Quebec;Canada | 1.2 | Seed | 2/29/2024 |
Neurona Therapeutics Inc. | San Francisco;California;United States | 120 | 2/8/2024 | |
Nextpoint Therapeutics Inc. | Cambridge;Massachusetts;United States | 42.5 | Series B | 2/14/2024 |
Orbis Medicines ApS | Copenhagen;Capital Region;Denmark | 28.1 | Seed | 2/29/2024 |
Pelage Pharmaceuticals Inc. | Los Angeles;California;United States | 16.75 | Series A | 2/27/2024 |
Profoundbio Co. Ltd. | Seattle;Washington;United States | 112 | Series B | 2/13/2024 |
Proniras Corp. | Seattle;Washington;United States | 4.65 | Series B | 2/1/2024 |
Pulsesight Therapeutics SAS | Paris;Île-de-France;France | Seed | 2/28/2024 | |
Sudo Biosciences Inc. | Carmel;Indiana;United States | 30 | 2/13/2024 | |
Xinnate AB | Lund;Skåne;Sweden | 9.55 | 2/7/2024 | |
Ability Pharmaceuticals SA | Barcelona;Catalonia;Spain | 7.7 | 3/11/2024 | |
Adocia SA | Lyon;Auvergne-Rhône-Alpes;France | 2.16 | 3/22/2024 | |
Aegis Life Inc. | San Diego;California;United States | 4.45 | Convertible promissory note offering | 3/19/2024 |
Aeovian Pharmaceuticals Inc. | Berkeley;California;United States | 50 | 3/28/2024 | |
Alithea Genomics SA | Lausanne, Switzerland | 3.2 | Seed | 3/14/2024 |
Alumis Inc. | South San Francisco;California;United States | 259 | Series C | 3/6/2024 |
Asgard Therapeutics AB | Lund;Skåne;Sweden | 32.8 | Series A | 3/14/2024 |
Atrogi AB | Solna;Stockholm;Sweden | 3/14/2024 | ||
Avenzo Therapeutics Inc. | San Diego;California;United States | 150 | Series A-1 | 3/26/2024 |
Brickbio Inc. | Waltham;Massachusetts;United States | 3/19/2024 | ||
Capstan Therapeutics Inc. | San Diego;California;United States | 175 | Series B | 3/20/2024 |
Clasp Therapeutics Corp. | Cambridge;Massachusetts;United States | 150 | Series A | 3/20/2024 |
Edgewood Oncology Inc. | Brookline;Massachusetts;United States | 20 | Series A | 3/26/2024 |
Eisbach Bio GmbH | Martinsried, Germany | 4.5 | 3/21/2024 | |
Engrail Therapeutics Inc. | San Diego;California;United States | 157 | Series B | 3/19/2024 |
Fogpharma Inc. | Cambridge;Massachusetts;United States | 145 | Series E | 3/1/2024 |
Mirador Therapeutics Inc. | San Diego;California;United States | 400 | 3/21/2024 | |
Mission Therapeutics Ltd. | Cambridge;England;United Kingdom | 32.1 | 3/14/2024 | |
Nocion Therapeutics Inc. | Watertown;Massachusetts;United States | 62 | Series B | 3/4/2024 |
Nouscom Srl | Basel;Basel-City;Switzerland | 7.6 | Series C | 3/21/2024 |
Portal Biotechnologies Inc. | Cambridge;Massachusetts;United States | 5 | Seed | 3/19/2024 |
Rakuten Medical Inc. | San Diego;California;United States | 119 | Series E | 3/7/2024 |
Relation Therapeutics Ltd. | London;England;United Kingdom | 35 | Seed | 3/14/2024 |
Senisca | Exeter;England;United Kingdom | 4.7 | 3/18/2024 | |
Siolta Therapeutics Inc. | San Carlos;California;United States | 12 | Series C | 3/12/2024 |
Sionna Therapeutics Inc. | Boston;Massachusetts;United States | 182 | Series C | 3/6/2024 |
Tempo Therapeutics Inc. | San Diego;California;United States | 12 | Series A | 3/20/2024 |
Tubulis GmbH | Munich;Bavaria;Germany | 139.4 | Series B2 | 3/14/2024 |
Alterome Therapeutics Inc. | San Diego;California;United States | 132 | Series B | 4/3/24 |
Asher Biotherapeutics Inc. | South San Francisco;California;United States | 55 | Series C | 4/16/24 |
Brise Pharmaceuticals Co. Ltd. | Shanghai;Shanghai;China | 20 | 4/23/24 | |
Conformation-X Therapeutics LLC | Canton;Massachusetts;United States | 3.65 | 4/3/24 | |
Corner Therapeutics Inc. | Watertown;Massachusetts;United States | 54 | Series A | 4/19/24 |
D3 Bio Inc. | Shanghai;Shanghai;China | 40 | 4/8/24 | |
Diagonal Therapeutics Inc. | Cambridge;Massachusetts;United States | 128 | Series A | 4/3/24 |
Endeavor Biomedicines Inc. | San Diego;California;United States | 132.5 | Series C | 4/24/24 |
Enterobiotix Ltd. | Glasgow;Scotland;United Kingdom | 34.2 | Series B | 4/4/24 |
Evergreen Theragnostics Inc. | Springfield;New Jersey;United States | 26 | 4/16/24 | |
Flindr Therapeutics BV | Oss, Netherlands | 21.4 | Series A | 4/24/24 |
Melt Pharmaceuticals Inc. | Nashville;Tennessee;United States | 24 | Series B | 4/2/24 |
Metsera Inc. | New York City;New York;United States | 290 | 4/18/24 | |
Neurenati Therapeutics | Montreal;Quebec;Canada | 1.2 | Seed | 4/18/24 |
Neurosterix | Genève;Geneva;Switzerland | 63 | Series A | 4/3/24 |
Obsidian Therapeutics Inc. | Cambridge;Massachusetts;United States | 160.5 | Series C | 4/3/24 |
Outrun Therapeutics Ltd. | Oxford;England;United Kingdom | 10 | Seed | 4/18/24 |
Pathios Therapeutics Ltd. | Oxford;England;United Kingdom | 25 | Series B | 4/18/24 |
Petalion Therapeutics Ltd. | Cambridge;England;United Kingdom | 25 | 4/9/24 | |
Red Arrow Therapeutics Inc. | Boston;Massachusetts;United States | 4.5 | Seed | 4/23/24 |
Rubedo Life Sciences Inc. | Sunnyvale;California;United States | 40 | Series A | 4/22/24 |
Salubris Biotherapeutics Inc. | Gaithersburg;Maryland;United States | 35 | 4/22/24 | |
Seaport Therapeutics | Boston;Massachusetts;United States | 100 | Series A | 4/9/24 |
Somite Therapeutics | Boston;Massachusetts;United States | 5.3 | Seed | 4/17/24 |
Synox Therapeutics Ltd. | Dublin;Leinster;Ireland | 75 | Series B | 4/22/24 |
Theolytics Ltd. | Helsinki;Uusimaa;Finland | 23.7 | 4/17/24 | |
Torl Biotherapeutics LLC | Los Angeles;California;United States | 158 | Series B-2 | 4/11/24 |
Xaira Therapeutics | San Francisco;California;United States | 1000 | 4/24/24 |